Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $144.9 million.

  • Immunocore Holdings' Accumulated Expenses fell 26.51% to $144.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.9 million, marking a year-over-year decrease of 26.51%. This contributed to the annual value of $185.5 million for FY2024, which is 54.82% up from last year.
  • Immunocore Holdings' Accumulated Expenses amounted to $144.9 million in Q3 2025, which was up 0.80% from $143.8 million recorded in Q2 2025.
  • Immunocore Holdings' Accumulated Expenses' 5-year high stood at $197.2 million during Q3 2024, with a 5-year trough of $76.7 million in Q4 2022.
  • Its 3-year average for Accumulated Expenses is $151.5 million, with a median of $144.4 million in 2025.
  • As far as peak fluctuations go, Immunocore Holdings' Accumulated Expenses surged by 56.14% in 2023, and later dropped by 26.51% in 2025.
  • Quarterly analysis of 4 years shows Immunocore Holdings' Accumulated Expenses stood at $76.7 million in 2022, then soared by 56.14% to $119.8 million in 2023, then soared by 54.82% to $185.5 million in 2024, then fell by 26.51% to $144.9 million in 2025.
  • Its Accumulated Expenses stands at $144.9 million for Q3 2025, versus $143.8 million for Q2 2025 and $118.3 million for Q1 2025.